iBio Announces Manufacturing Collaboration with Aethlon Medical
October 16 2017 - 7:15AM
iBio, Inc. (NYSE AMERICAN:IBIO), a leading provider of plant-based
biotechnology for developing and manufacturing biological products,
announced the establishment of an agreement with Aethlon Medical,
Inc. (Nasdaq:AEMD) to support potential large-scale production of
the Aethlon Hemopurifier® blood purification device. Aethlon
Medical is a therapeutic technology company focused on unmet needs
in global health and biodefense.
The companies previously confirmed the
feasibility of using a proprietary recombinant lectin protein,
Galanthus nivalis agglutinin (GNA), produced with iBio’s unique
plant-based technology, to increase the performance of Aethlon’s
Hemopurifier® blood purification device. Scientists from the two
companies worked together to produce and screen a panel of
recombinantly produced lectin isoforms to improve binding capacity
and to replace reliance on less effective extracted mixtures.
Jim Joyce, Chairman and CEO of Aethlon, stated,
“The production of recombinant GNA in iBio’s large-scale
manufacturing facility establishes a pathway for us to access a
consistent, high quality supply that can support our long-term
clinical and commercialization objectives.”
Dr. Barry Holtz, President of iBio CDMO, said,
“Aethlon’s clinical success and product development expertise is
now backed by our cGMP compliant therapeutic protein production
capacity and expanded classified manufacturing space. This is
an ideal combination for Aethlon to deliver a new therapeutic
approach to pandemic disease and biothreats.”
Aethlon has recently received an FDA Expedited
Access Pathway Designation for its Hemopurifier® device, a single
use cartridge that can capture a broad spectrum of highly
glycosylated viruses including influenza and hemorrhagic fevers,
such as Ebola virus, to reduce viral load in the circulatory
system. Aethlon is also investigating the use of the
Hemopurifier® device to reduce the presence of circulating,
tumor-derived exosomes, which contribute to immune-suppression and
metastasis.
About Aethlon Medical, Inc.
Aethlon Medical is focused on addressing unmet
needs in global health and biodefense. The Aethlon Hemopurifier® is
a first-in-class therapeutic device designed to address
life-threatening viral infections. The United States Food and
Drug Administration (FDA) has designated the Hemopurifier® to an
Expedited Access Pathway (EAP) related to the treatment of
life-threatening viruses that are not addressed with approved
therapies.
In collaboration with leading government and
non-government research institutes, Aethlon has validated the
ability of the Hemopurifier® to capture a broad-spectrum of
pandemic influenza viruses, mosquito-borne viruses and deadly
hemorrhagic viruses. Based on its use to treat Ebola virus,
the Hemopurifier® was named a "Top 25 Invention" and one of the
"Eleven Most Remarkable Advances in Healthcare," by TIME
Magazine.
Aethlon is also investigating the potential
therapeutic use of the Hemopurifier® to reduce the presence of
tumor-derived exosomes, which contribute to immune-suppression and
the spread of metastasis in cancer patients. Additionally,
Aethlon is the majority owner of Exosome Sciences, Inc. (ESI),
which is focused on the discovery of exosomal biomarkers to
diagnose and monitor cancer and neurological disorders, including
Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy
(CTE). Additional information can be found online at
www.AethlonMedical.com and www.ExosomeSciences.com. You can
also connect with Aethlon on Twitter, LinkedIn, Facebook and
Google+.
About iBio, Inc.
iBio, a leader in developing plant-based
biopharmaceuticals, provides a range of product and process
development, analytical, and manufacturing services at the
large-scale development and manufacturing facility of its
subsidiary iBio CDMO, LLC. in Bryan, Texas. The facility
houses laboratory and pilot-scale operations, as well as
large-scale automated hydroponic systems capable of growing over
four million plants as "in process inventory" and delivering over
300 kilograms of therapeutic protein pharmaceutical active
ingredient per year.
iBio applies its technology for the benefit of
its clients and the advancement of its own product interests. The
Company’s pipeline is comprised of proprietary candidates for the
treatment of a range of fibrotic diseases including idiopathic
pulmonary fibrosis, systemic sclerosis, and scleroderma.
IBIO-CFB03, based on the Company's proprietary gene expression
technology, is the Company’s lead therapeutic candidate being
advanced for IND development.
Further information is available at:
www.ibioinc.com
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC.
MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS
INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE
FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE
COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE
NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF
PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD
AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE
COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
ICR, Inc. (Investor and Media Inquiries):
Stephanie Carrington Tel. +1 646-277-1282
stephanie.carrington@icrinc.com
James HeinsTel. +1 203-682-8251James.Heins@icrinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024